Safety and Efficacy of Mirogabalin for Peripheral Neuropathic Pain: Pooled Analysis of Two Pivotal Phase III Studies

Mirogabalin besylate has been approved in several countries to treat peripheral neuropathic pain. This pooled analysis, using data from the two pivotal Phase III studies in Asian patients with diabetic peripheral neuropathic pain and post-herpetic neuralgia, aimed to provide clinicians with more det...

Full description

Saved in:
Bibliographic Details
Published in:Clinical therapeutics 2021-05, Vol.43 (5), p.822-835.e16
Main Authors: Kato, Jitsu, Baba, Masayuki, Kuroha, Masanori, Kakehi, Yoshihiro, Murayama, Emiko, Wasaki, Yosuke, Ohwada, Shoichi
Format: Article
Language:English
Subjects:
Adverse events
Alpha 2 delta (α2δ) ligand
Analgesics
Diabetes mellitus
Diabetic neuropathy
Dosage
Drug dosages
Edema
Informed consent
Ligands
Mirogabalin
Nervous system
Neuralgia
Pain
Patients
Peripheral neuropathic pain
Phase III study
Placebos
Pooled analysis
Questionnaires
Safety
Statistical analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c425t-df2cd4bd1bb1b6855019814fb4ed04fa0a4ba93a45fda02198fac5646100b56f3
cites cdi_FETCH-LOGICAL-c425t-df2cd4bd1bb1b6855019814fb4ed04fa0a4ba93a45fda02198fac5646100b56f3
container_end_page 835.e16
container_issue 5
container_start_page 822
container_title Clinical therapeutics
container_volume 43
creator Kato, Jitsu
Baba, Masayuki
Kuroha, Masanori
Kakehi, Yoshihiro
Murayama, Emiko
Wasaki, Yosuke
Ohwada, Shoichi
description Mirogabalin besylate has been approved in several countries to treat peripheral neuropathic pain. This pooled analysis, using data from the two pivotal Phase III studies in Asian patients with diabetic peripheral neuropathic pain and post-herpetic neuralgia, aimed to provide clinicians with more detailed and precise information relating to mirogabalin's safety and efficacy. Data were pooled from 2 multicenter, double-blind, placebo-controlled, parallel-group, 14-week treatment studies of mirogabalin conducted at ∼350 study sites (Japan, South Korea, Taiwan, Singapore, Malaysia, and Thailand). Eligible patients in both studies were randomized in a 2:1:1:1 ratio, stratified according to a baseline average daily pain score (ADPS) of
doi_str_mv 10.1016/j.clinthera.2021.03.015
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2535830983</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0149291821001272</els_id><sourcerecordid>2561924300</sourcerecordid><originalsourceid>FETCH-LOGICAL-c425t-df2cd4bd1bb1b6855019814fb4ed04fa0a4ba93a45fda02198fac5646100b56f3</originalsourceid><addsrcrecordid>eNqFkUGL1DAYhoMoOI7-BgNevLQmbdJtvA3LqgOrFnYFb-Fr8sXJ0G3GJF2Zf2_KiAcvnnJ5n_fjzUPIa85qznj37libyc_5gBHqhjW8Zm3NuHxCNry_UhXn4vtTsmFcqKpRvH9OXqR0ZIy1SjYbku_AYT5TmC29cc4bMGcaHP3sY_gBI5Rq6kKkA0Z_Wm9M9AsuMZwgH7yhA_j5PR1CmNDS3QzTOfm08ve_Ah38Y8gFGA6QkO73e3qXF-sxvSTPHEwJX_15t-Tbh5v760_V7deP--vdbWVEI3NlXWOsGC0fRz52vZSMq54LNwq0TDhgIEZQLQjpLJTlqndgZCc6ztgoO9duydtL7ymGnwumrB98MjhNMGNYkm5kK_uWqb4t0Tf_RI9hiWXQmuq4akRbvmxLri4pE0NKEZ0-Rf8A8aw506sNfdR_bejVhmatLjYKubuQWPY-eow6GY-zQesjmqxt8P_t-A2dlpeQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2561924300</pqid></control><display><type>article</type><title>Safety and Efficacy of Mirogabalin for Peripheral Neuropathic Pain: Pooled Analysis of Two Pivotal Phase III Studies</title><source>ScienceDirect Journals</source><creator>Kato, Jitsu ; Baba, Masayuki ; Kuroha, Masanori ; Kakehi, Yoshihiro ; Murayama, Emiko ; Wasaki, Yosuke ; Ohwada, Shoichi</creator><creatorcontrib>Kato, Jitsu ; Baba, Masayuki ; Kuroha, Masanori ; Kakehi, Yoshihiro ; Murayama, Emiko ; Wasaki, Yosuke ; Ohwada, Shoichi</creatorcontrib><description>Mirogabalin besylate has been approved in several countries to treat peripheral neuropathic pain. This pooled analysis, using data from the two pivotal Phase III studies in Asian patients with diabetic peripheral neuropathic pain and post-herpetic neuralgia, aimed to provide clinicians with more detailed and precise information relating to mirogabalin's safety and efficacy. Data were pooled from 2 multicenter, double-blind, placebo-controlled, parallel-group, 14-week treatment studies of mirogabalin conducted at ∼350 study sites (Japan, South Korea, Taiwan, Singapore, Malaysia, and Thailand). Eligible patients in both studies were randomized in a 2:1:1:1 ratio, stratified according to a baseline average daily pain score (ADPS) of &lt;6 or ≥6, to placebo, mirogabalin 15-mg once daily (QD), mirogabalin 10-mg twice daily (BID), or mirogabalin 15-mg BID treatment groups. Safety was assessed based on treatment-emergent adverse events identified from the adverse events collected throughout both studies. The primary efficacy end point of both studies was the change from baseline in ADPS at week 14. In total, 1587 patients (824 with diabetic peripheral neuropathic pain; 763 with post-herpetic neuralgia) who received at least 1 dose of study drug were analyzed (633 received placebo, 954 treated with mirogabalin). Treatment-emergent adverse events included somnolence (3.8%, 10.8%, 14.5%, and 19.1%) and dizziness (2.7%, 5.7%, 9.1%, and 13.1%) in patients receiving placebo, mirogabalin 15 mg QD, mirogabalin 10 mg BID, and mirogabalin 15 mg BID, respectively. In patients treated with mirogabalin 15 mg QD, 2 (0.6%) of 316 patients discontinued due to somnolence. In the mirogabalin 10-mg BID group, somnolence, edema, and peripheral edema each resulted in 3 (0.9%) of 318 patient discontinuations. In the mirogabalin 15-mg BID group, 6 (1.9%) of 320 patients discontinued due to dizziness and 3 (0.9%) due to somnolence. At week 14, mirogabalin 10 mg BID and 15 mg BID statistically significantly improved ADPS versus placebo, with least squares mean changes (95% CI) of −0.31 (−0.55, −0.08) and −0.63 (−0.86, −0.40). Post hoc analysis showed a statistically significant difference 2 days after administration in the mirogabalin 10-mg and 15-mg BID groups compared with placebo. Female sex, age ≥65 years, and baseline weight &lt;60 kg may influence the safety of mirogabalin, particularly regarding the incidence of somnolence and dizziness, but had no notable impact on efficacy. ClinicalTrials.gov identifiers: NCT02318706 and NCT02318719. This pooled analysis showed that mirogabalin was efficacious and well-tolerated by Asian patients with peripheral neuropathic pain.</description><identifier>ISSN: 0149-2918</identifier><identifier>EISSN: 1879-114X</identifier><identifier>DOI: 10.1016/j.clinthera.2021.03.015</identifier><language>eng</language><publisher>Bridgewater: Elsevier Inc</publisher><subject>Adverse events ; Alpha 2 delta (α2δ) ligand ; Analgesics ; Diabetes mellitus ; Diabetic neuropathy ; Dosage ; Drug dosages ; Edema ; Informed consent ; Ligands ; Mirogabalin ; Nervous system ; Neuralgia ; Pain ; Patients ; Peripheral neuropathic pain ; Phase III study ; Placebos ; Pooled analysis ; Questionnaires ; Safety ; Statistical analysis</subject><ispartof>Clinical therapeutics, 2021-05, Vol.43 (5), p.822-835.e16</ispartof><rights>2021 The Authors</rights><rights>2021. The Authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c425t-df2cd4bd1bb1b6855019814fb4ed04fa0a4ba93a45fda02198fac5646100b56f3</citedby><cites>FETCH-LOGICAL-c425t-df2cd4bd1bb1b6855019814fb4ed04fa0a4ba93a45fda02198fac5646100b56f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Kato, Jitsu</creatorcontrib><creatorcontrib>Baba, Masayuki</creatorcontrib><creatorcontrib>Kuroha, Masanori</creatorcontrib><creatorcontrib>Kakehi, Yoshihiro</creatorcontrib><creatorcontrib>Murayama, Emiko</creatorcontrib><creatorcontrib>Wasaki, Yosuke</creatorcontrib><creatorcontrib>Ohwada, Shoichi</creatorcontrib><title>Safety and Efficacy of Mirogabalin for Peripheral Neuropathic Pain: Pooled Analysis of Two Pivotal Phase III Studies</title><title>Clinical therapeutics</title><description>Mirogabalin besylate has been approved in several countries to treat peripheral neuropathic pain. This pooled analysis, using data from the two pivotal Phase III studies in Asian patients with diabetic peripheral neuropathic pain and post-herpetic neuralgia, aimed to provide clinicians with more detailed and precise information relating to mirogabalin's safety and efficacy. Data were pooled from 2 multicenter, double-blind, placebo-controlled, parallel-group, 14-week treatment studies of mirogabalin conducted at ∼350 study sites (Japan, South Korea, Taiwan, Singapore, Malaysia, and Thailand). Eligible patients in both studies were randomized in a 2:1:1:1 ratio, stratified according to a baseline average daily pain score (ADPS) of &lt;6 or ≥6, to placebo, mirogabalin 15-mg once daily (QD), mirogabalin 10-mg twice daily (BID), or mirogabalin 15-mg BID treatment groups. Safety was assessed based on treatment-emergent adverse events identified from the adverse events collected throughout both studies. The primary efficacy end point of both studies was the change from baseline in ADPS at week 14. In total, 1587 patients (824 with diabetic peripheral neuropathic pain; 763 with post-herpetic neuralgia) who received at least 1 dose of study drug were analyzed (633 received placebo, 954 treated with mirogabalin). Treatment-emergent adverse events included somnolence (3.8%, 10.8%, 14.5%, and 19.1%) and dizziness (2.7%, 5.7%, 9.1%, and 13.1%) in patients receiving placebo, mirogabalin 15 mg QD, mirogabalin 10 mg BID, and mirogabalin 15 mg BID, respectively. In patients treated with mirogabalin 15 mg QD, 2 (0.6%) of 316 patients discontinued due to somnolence. In the mirogabalin 10-mg BID group, somnolence, edema, and peripheral edema each resulted in 3 (0.9%) of 318 patient discontinuations. In the mirogabalin 15-mg BID group, 6 (1.9%) of 320 patients discontinued due to dizziness and 3 (0.9%) due to somnolence. At week 14, mirogabalin 10 mg BID and 15 mg BID statistically significantly improved ADPS versus placebo, with least squares mean changes (95% CI) of −0.31 (−0.55, −0.08) and −0.63 (−0.86, −0.40). Post hoc analysis showed a statistically significant difference 2 days after administration in the mirogabalin 10-mg and 15-mg BID groups compared with placebo. Female sex, age ≥65 years, and baseline weight &lt;60 kg may influence the safety of mirogabalin, particularly regarding the incidence of somnolence and dizziness, but had no notable impact on efficacy. ClinicalTrials.gov identifiers: NCT02318706 and NCT02318719. This pooled analysis showed that mirogabalin was efficacious and well-tolerated by Asian patients with peripheral neuropathic pain.</description><subject>Adverse events</subject><subject>Alpha 2 delta (α2δ) ligand</subject><subject>Analgesics</subject><subject>Diabetes mellitus</subject><subject>Diabetic neuropathy</subject><subject>Dosage</subject><subject>Drug dosages</subject><subject>Edema</subject><subject>Informed consent</subject><subject>Ligands</subject><subject>Mirogabalin</subject><subject>Nervous system</subject><subject>Neuralgia</subject><subject>Pain</subject><subject>Patients</subject><subject>Peripheral neuropathic pain</subject><subject>Phase III study</subject><subject>Placebos</subject><subject>Pooled analysis</subject><subject>Questionnaires</subject><subject>Safety</subject><subject>Statistical analysis</subject><issn>0149-2918</issn><issn>1879-114X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqFkUGL1DAYhoMoOI7-BgNevLQmbdJtvA3LqgOrFnYFb-Fr8sXJ0G3GJF2Zf2_KiAcvnnJ5n_fjzUPIa85qznj37libyc_5gBHqhjW8Zm3NuHxCNry_UhXn4vtTsmFcqKpRvH9OXqR0ZIy1SjYbku_AYT5TmC29cc4bMGcaHP3sY_gBI5Rq6kKkA0Z_Wm9M9AsuMZwgH7yhA_j5PR1CmNDS3QzTOfm08ve_Ah38Y8gFGA6QkO73e3qXF-sxvSTPHEwJX_15t-Tbh5v760_V7deP--vdbWVEI3NlXWOsGC0fRz52vZSMq54LNwq0TDhgIEZQLQjpLJTlqndgZCc6ztgoO9duydtL7ymGnwumrB98MjhNMGNYkm5kK_uWqb4t0Tf_RI9hiWXQmuq4akRbvmxLri4pE0NKEZ0-Rf8A8aw506sNfdR_bejVhmatLjYKubuQWPY-eow6GY-zQesjmqxt8P_t-A2dlpeQ</recordid><startdate>202105</startdate><enddate>202105</enddate><creator>Kato, Jitsu</creator><creator>Baba, Masayuki</creator><creator>Kuroha, Masanori</creator><creator>Kakehi, Yoshihiro</creator><creator>Murayama, Emiko</creator><creator>Wasaki, Yosuke</creator><creator>Ohwada, Shoichi</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>202105</creationdate><title>Safety and Efficacy of Mirogabalin for Peripheral Neuropathic Pain: Pooled Analysis of Two Pivotal Phase III Studies</title><author>Kato, Jitsu ; Baba, Masayuki ; Kuroha, Masanori ; Kakehi, Yoshihiro ; Murayama, Emiko ; Wasaki, Yosuke ; Ohwada, Shoichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c425t-df2cd4bd1bb1b6855019814fb4ed04fa0a4ba93a45fda02198fac5646100b56f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adverse events</topic><topic>Alpha 2 delta (α2δ) ligand</topic><topic>Analgesics</topic><topic>Diabetes mellitus</topic><topic>Diabetic neuropathy</topic><topic>Dosage</topic><topic>Drug dosages</topic><topic>Edema</topic><topic>Informed consent</topic><topic>Ligands</topic><topic>Mirogabalin</topic><topic>Nervous system</topic><topic>Neuralgia</topic><topic>Pain</topic><topic>Patients</topic><topic>Peripheral neuropathic pain</topic><topic>Phase III study</topic><topic>Placebos</topic><topic>Pooled analysis</topic><topic>Questionnaires</topic><topic>Safety</topic><topic>Statistical analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kato, Jitsu</creatorcontrib><creatorcontrib>Baba, Masayuki</creatorcontrib><creatorcontrib>Kuroha, Masanori</creatorcontrib><creatorcontrib>Kakehi, Yoshihiro</creatorcontrib><creatorcontrib>Murayama, Emiko</creatorcontrib><creatorcontrib>Wasaki, Yosuke</creatorcontrib><creatorcontrib>Ohwada, Shoichi</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest Health Management Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kato, Jitsu</au><au>Baba, Masayuki</au><au>Kuroha, Masanori</au><au>Kakehi, Yoshihiro</au><au>Murayama, Emiko</au><au>Wasaki, Yosuke</au><au>Ohwada, Shoichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and Efficacy of Mirogabalin for Peripheral Neuropathic Pain: Pooled Analysis of Two Pivotal Phase III Studies</atitle><jtitle>Clinical therapeutics</jtitle><date>2021-05</date><risdate>2021</risdate><volume>43</volume><issue>5</issue><spage>822</spage><epage>835.e16</epage><pages>822-835.e16</pages><issn>0149-2918</issn><eissn>1879-114X</eissn><abstract>Mirogabalin besylate has been approved in several countries to treat peripheral neuropathic pain. This pooled analysis, using data from the two pivotal Phase III studies in Asian patients with diabetic peripheral neuropathic pain and post-herpetic neuralgia, aimed to provide clinicians with more detailed and precise information relating to mirogabalin's safety and efficacy. Data were pooled from 2 multicenter, double-blind, placebo-controlled, parallel-group, 14-week treatment studies of mirogabalin conducted at ∼350 study sites (Japan, South Korea, Taiwan, Singapore, Malaysia, and Thailand). Eligible patients in both studies were randomized in a 2:1:1:1 ratio, stratified according to a baseline average daily pain score (ADPS) of &lt;6 or ≥6, to placebo, mirogabalin 15-mg once daily (QD), mirogabalin 10-mg twice daily (BID), or mirogabalin 15-mg BID treatment groups. Safety was assessed based on treatment-emergent adverse events identified from the adverse events collected throughout both studies. The primary efficacy end point of both studies was the change from baseline in ADPS at week 14. In total, 1587 patients (824 with diabetic peripheral neuropathic pain; 763 with post-herpetic neuralgia) who received at least 1 dose of study drug were analyzed (633 received placebo, 954 treated with mirogabalin). Treatment-emergent adverse events included somnolence (3.8%, 10.8%, 14.5%, and 19.1%) and dizziness (2.7%, 5.7%, 9.1%, and 13.1%) in patients receiving placebo, mirogabalin 15 mg QD, mirogabalin 10 mg BID, and mirogabalin 15 mg BID, respectively. In patients treated with mirogabalin 15 mg QD, 2 (0.6%) of 316 patients discontinued due to somnolence. In the mirogabalin 10-mg BID group, somnolence, edema, and peripheral edema each resulted in 3 (0.9%) of 318 patient discontinuations. In the mirogabalin 15-mg BID group, 6 (1.9%) of 320 patients discontinued due to dizziness and 3 (0.9%) due to somnolence. At week 14, mirogabalin 10 mg BID and 15 mg BID statistically significantly improved ADPS versus placebo, with least squares mean changes (95% CI) of −0.31 (−0.55, −0.08) and −0.63 (−0.86, −0.40). Post hoc analysis showed a statistically significant difference 2 days after administration in the mirogabalin 10-mg and 15-mg BID groups compared with placebo. Female sex, age ≥65 years, and baseline weight &lt;60 kg may influence the safety of mirogabalin, particularly regarding the incidence of somnolence and dizziness, but had no notable impact on efficacy. ClinicalTrials.gov identifiers: NCT02318706 and NCT02318719. This pooled analysis showed that mirogabalin was efficacious and well-tolerated by Asian patients with peripheral neuropathic pain.</abstract><cop>Bridgewater</cop><pub>Elsevier Inc</pub><doi>10.1016/j.clinthera.2021.03.015</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0149-2918
ispartof Clinical therapeutics, 2021-05, Vol.43 (5), p.822-835.e16
issn 0149-2918
1879-114X
language eng
recordid cdi_proquest_miscellaneous_2535830983
source ScienceDirect Journals
subjects Adverse events
Alpha 2 delta (α2δ) ligand
Analgesics
Diabetes mellitus
Diabetic neuropathy
Dosage
Drug dosages
Edema
Informed consent
Ligands
Mirogabalin
Nervous system
Neuralgia
Pain
Patients
Peripheral neuropathic pain
Phase III study
Placebos
Pooled analysis
Questionnaires
Safety
Statistical analysis
title Safety and Efficacy of Mirogabalin for Peripheral Neuropathic Pain: Pooled Analysis of Two Pivotal Phase III Studies
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T18%3A14%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20Efficacy%20of%20Mirogabalin%20for%20Peripheral%20Neuropathic%20Pain:%20Pooled%20Analysis%20of%20Two%20Pivotal%20Phase%20III%20Studies&rft.jtitle=Clinical%20therapeutics&rft.au=Kato,%20Jitsu&rft.date=2021-05&rft.volume=43&rft.issue=5&rft.spage=822&rft.epage=835.e16&rft.pages=822-835.e16&rft.issn=0149-2918&rft.eissn=1879-114X&rft_id=info:doi/10.1016/j.clinthera.2021.03.015&rft_dat=%3Cproquest_cross%3E2561924300%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c425t-df2cd4bd1bb1b6855019814fb4ed04fa0a4ba93a45fda02198fac5646100b56f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2561924300&rft_id=info:pmid/&rfr_iscdi=true